Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 5:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 5,229 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control/Placebo group Clear all

Conditions: Hay Fever, Perennial Allergic Rhinitis
Interventions: Ciclesonide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 2 Years to 5 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 3
States / cities: Long Beach, California • Normal, Illinois • San Antonio, Texas

Conditions: Acne Vulgaris
Interventions: Onexton, Clindamycin/benzoyl peroxide gel, Placebo; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 862 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 17
States / cities: Phoenix, Arizona • Chula Vista, California • La Mesa, California + 14 more

Conditions: Heart Failure, Congestive
Interventions: Enoximone, Metoprolol succinate, Placebo to match enoximone, Placebo to match metoprolol succinate; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 2
States / cities: Denver, Colorado • Salt Lake City, Utah

Conditions: Tachycardia Atrial, Atrial Fibrillation, Atrial Flutter With Rapid Ventricular Response
Interventions: Magnesium Sulfate 2 G, Magnesium Sulfate 4 G, Saline; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Oak Lawn, Illinois

Conditions: Vulvar Lichen Sclerosus
Interventions: Fractionated CO2-laser, Clobetasol Propionate 0.05% Ointment; Device · Drug
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 10
States / cities: San Diego, California • Washington D.C., District of Columbia • Chicago, Illinois + 7 more

Conditions: Chronic Pain
Interventions: Sham Phoenix Laser Treatment, Active Phoenix Laser Treatment; Device
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: COVID-19 Pneumonia
Interventions: PF-06650833, Matching Placebo; Drug
Lead sponsor: Giovanni Franchin, M.D, Ph.D; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Coronary Atherosclerosis
Interventions: Rimonabant (SR141716), Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 839 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Hidradenitis
Interventions: Amlitelimab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 12
States / cities: Phoenix, Arizona • Fremont, California • Margate, Florida + 9 more

Conditions: Parkinson's Disease, Movement Disorder Syndrome
Interventions: Istradefylline (KW-6002); Drug
Lead sponsor: Kyowa Kirin, Inc.; Industry
Eligibility: 30 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Rheumatoid Arthritis
Interventions: fostamatinib, placebo, fostamatinib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 913 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 57
States / cities: Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 54 more

Conditions: Diabetes Mellitus
Interventions: HM11260C, Placebo, Victoza; Drug
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: California City, California

Conditions: Hypertension
Interventions: Nebivolol; Drug
Lead sponsor: Mylan Bertek Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Heart Failure
Interventions: Sodium Zirconium Cyclosilicate, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 150 Years
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 14
States / cities: National City, California • Stanford, California • Waterbury, Connecticut + 11 more

Conditions: Major Depressive Disorder
Interventions: AZD2066, Placebo, Duloxetine; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 13
States / cities: Garden Grove, California • San Diego, California • Jacksonville, Florida + 10 more

Conditions: Rheumatoid Arthritis
Interventions: INCB018424, Placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 12
States / cities: Huntsville, Alabama • Upland, California • Gainesville, Florida + 9 more

Conditions: Alzheimer's Dementia
Interventions: Resonator; Device
Lead sponsor: pico-tesla Magnetic Therapies, LLC; Industry
Eligibility: 55 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Episodic Cluster Headache
Interventions: Civamide (Zucapsaicin), Sodium Chloride; Drug
Lead sponsor: Winston Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 6
States / cities: San Francisco, California • Santa Monica, California • Denver, Colorado + 3 more

Conditions: Heart Failure
Interventions: Vericiguat (BAY1021189) (1.25 mg), Vericiguat (BAY1021189) (5 mg), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 18
States / cities: Fountain Valley, California • Wilmington, Delaware • Fort Lauderdale, Florida + 15 more

Conditions: Contraception, Pain, Acute, Anesthesia, Local
Interventions: Buffered Lidocaine, Sham Comparator, Unbuffered lidocaine, Xylocaine jelly 2%, Surgilube; Drug · Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 204 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Dermatitis, Atopic
Interventions: PF-04965842 100 mg, PF-04965842 200 mg, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 387 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 29
States / cities: Birmingham, Alabama • Encinitas, California • San Diego, California + 21 more

Conditions: Depression, Traumatic Brain Injury
Interventions: aerobic exercise, stretching and flexibility program; Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 14 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Infertility, Vitamin D Deficiency
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 38 Years · Female only
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 3
States / cities: Chicago, Illinois

Conditions: Irritable Bowel Syndrome Characterized by Constipation
Interventions: Linaclotide, Placebo; Drug
Lead sponsor: Ironwood Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 79
States / cities: Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more

Search by objective public record fields.

Safety and Tolerability of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis (2-5 Years Old) (BY9010/M1-416)

Double-blind Placebo-controlled Trial of Generic Clindamycin/Benzoyl Peroxide Gel Versus Onexton Gel in Acne Vulgaris

Enoximone Plus Extended-Release Metoprolol Succinate in Subjects With Advanced Chronic Heart Failure

Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR

Fractionated CO2 Laser With and Without Clobetasol for Treatment of Vulvar Lichen Sclerosus

Low-level Laser Therapy in Patients With Chronic Fibromyalgia

IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation.

STRADIVARIUS (Strategy To Reduce Atherosclerosis Development InVolving Administration of Rimonabant - the Intravascular Ultrasound Study)

Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

A Study of Istradefylline (KW-6002) as Monotherapy in Parkinson's Disease (PD) Patients

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.

A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

A Study of the Efficacy and Safety of Nebivolol Added to Existing Antihypertensive Treatment in Patients With Hypertension

Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure

6-week Study Treatment to Evaluate the Safety and Effectiveness of AZD2066 in Patients With Major Depressive Disorder

A Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects With Active Rheumatoid Arthritis

Safety and Efficacy Study of Magnetic Fields to Treat Alzheimer's Disease

Intranasal Civamide for Episodic Cluster Headache

Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)

Empathy Through Pain Control: Lidocaine Paracervical Block for IUD Placements

Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis

Exercise Training in Depressed Traumatic Brain Injury Survivors

Effect of Vitamin D Supplementation on In-vitro Fertilization (IVF) Outcomes

A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)